The average patient with advanced pancreatic cancer won’t live longer than a year. Photo: Alamy

Pancreatic cancer: new drug therapy significantly slows the spread of the disease, study finds

  • A third of the patients who received the medication olaparib were still alive two years into the clinical trial
  • Those patients had their disease under control for almost twice as long as those who received the placebo
Topic |   Health and wellness

TOP PICKS

The average patient with advanced pancreatic cancer won’t live longer than a year. Photo: Alamy
READ FULL ARTICLE